Home8QQ • FRA
add
AbCellera Biologics Inc
Previous close
€2.08
Day range
€2.14 - €2.14
Year range
€1.91 - €4.49
Market cap
708.88M USD
Avg Volume
1.25K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 5.05M | -44.98% |
Operating expense | -271.00K | -101.02% |
Net income | -34.21M | 27.44% |
Net profit margin | -677.43 | -31.88% |
Earnings per share | -0.12 | 25.00% |
EBITDA | -26.04M | 55.50% |
Effective tax rate | 26.95% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 625.61M | -17.75% |
Total assets | 1.36B | -8.57% |
Total liabilities | 304.47M | -9.32% |
Total equity | 1.06B | — |
Shares outstanding | 297.99M | — |
Price to book | 0.58 | — |
Return on assets | -7.40% | — |
Return on capital | -8.97% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -34.21M | 27.44% |
Cash from operations | -8.00M | 59.21% |
Cash from investing | 35.70M | 246.79% |
Cash from financing | 4.14M | 10.01% |
Net change in cash | 29.68M | 175.92% |
Free cash flow | -72.44M | -28,861.47% |
About
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
CEO
Founded
2012
Headquarters
Website
Employees
596
